LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer

E. Elez, J. Schellens, R. van Geel,J. Bendell,A. Spreafico,M. Schuler, T. Yoshino,J-P. Delord,Y. Yamada, M. Lolkema,J.E. Faris, F. Eskens,S. Sharma, R. Yaeger,H-J. Lenz,Z. Wainberg,E. Avsar, A. Chatterjee, S. Jaeger,T. Demuth, J. Tabernero

Annals of Oncology(2015)

引用 16|浏览19
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要